




## MEANINGFUL INVOLVEMENT OF INDONESIAN DRUGS USER NETWORK IN RESPOND AND AVAILABILITY HCV TREATMENT ACCESS IN INDONESIA

PKNI (Indonesian Drugs User Network)

Andika Prayudi Wibaskara

[dikamuska@gmail.com](mailto:dikamuska@gmail.com)

INSHU Symposium, Cascais - Portugal

2018, 17 Sep – 21 Sep




## BACKGROUND

- HCV Advocacy by Drugs user Network begin 2011 in Indonesia
- Government through MoH give good attention on HCV and put community in strategic position
- Indonesian Hepatitis biggest base Policy is Ministry of Health regulation No. 53, 2015
- 2016 MoH start establish Sub directorate of Hepatitis
- National prevalence of HCV is 1.01%, and IBBS for KAPs 2015 is our Nationaly data base for Hepatitis C.
- Studie of Peer Driven Intervention around Jakarta among PWID is found 89.2% HCV, 52.3% co-infection HIV-HCV, 88.1% had never been treated
- HCV DAA treatment quality and availability is limited.
- Heptology expert doctor (Kgeh) is only around 136 person in Indonesia.
- Aproximately more the 80% of this HCV Advocacy activity supported by Coalition Plus (C+) and other partners international development partners.



## METHODS

- Build Partnerships with Government such with Sub directorate of Hepatitis MoH
- Community facilitated meets between sovaldi originator with MoH about Sovaldi prices in Indonesia.
- Various approaches in strategic positions continue processed, such conduct National Consultation Meeting on HCV
- Encouraging Indonesian FDA for DAA registration process.
- Involve gather with MoH and Expert panel for procurement and distribution of DAA programs
- Push HCV is being one of indicator National HIV Intervention
- Street protests for Indonesian FDA, About, to give Daclatasvir fast track registration in Indonesia
- And continue do it series of HCV raising awareness activities.




## RESULT

- Several HCV related studies, such as the Peer Driven Intervention Study and the economic costs of HCV treatment
- Sovaldi drugs decided agree for 400 US Dollar and recently price is 385 US Dollar.
- Involved on develop draft 53<sup>rd</sup> 2015 MoH regulation and DAA treatment guideline
- 6000 free DAA treatment program is start 2017 around 6 provinces and 2018 being 12 Provinces
- Invited by MoH to hepatitis expert committee meeting
- Daclatasvir is being registred and also inside for 2018 MoH Sub Directorate budget plan and now is already affordable for 4200 Daclatasvir for DAA treatment as MoH Program on 2018 for 12 province in Indonesia
- Indonesian Hepatolog Association (PPHI) give permission for Internist with training certificate, for give DAA prescription and doing control treatment process around 12 province. (PKNI-PPHI-MoH)
- Trained 80 medical officers and Internist about DAA and trained 60 Peer Educators and 200 peoples is involving HCV public discussion around 6 provinces
- HCV is be one indicator of National HIV intervention
- Done National Consultation Meeting on HCV 2015 and 2018
- Sign MoU Between PKNI and Ditjenpas, Ministry of Law and Human Right, for HCV test and treatment access inside Indonesian prison, start in Jakarta.

## CONCLUSION

- Meaningful involvement of People using drugs Community on HCV advocacy is give real impact especially for our peers
- Partnerships and build networking is important part of success in this HCV advocacy
- Our existence and this process should be maintaine and continue make sure role of community and needs is accommodated in Indonesia
- Hopefully community voice, efforts and involvement can support Indonesian Government, regarding Indonesian role in achieving the Global Target of HCV elimination by 2030





# TERIMA KASIH

DIRECT ACTING ANTIVIRAL FOR HEALTHY AND LIFE

[WWW.PKNI.ORG](http://WWW.PKNI.ORG)  
[HTTP://NAPZADANHATI.INFO](http://NAPZADANHATI.INFO)

ESPECIALLY FOR :  
HEALTH ADVOCACY PKNI TEAM  
COALITION PLUS (C+)  
SUB DIRECTORATE OF HEPATITIS AND ISP MOH INDONESIA  
INHSU